Anika to defend patent infringement lawsuit for MONOVISC product

Download PDF Copy

Editorial Checklist

Reviewed

Anika Therapeutics, Inc.Jul 13 2010

NewsGuard 100/100 Score

Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in products for tissue protection, healing and repair, based on hyaluronic acid ("HA") technology, announced today that they had been served with a complaint alleging patent infringement with respect to the MONOVISC product by Genzyme Corporation. This complaint was filed in the United States District Court for the District of Massachusetts on July 7, 2010. The company intends to vigorously defend the lawsuit and the MONOVISC product franchise.

“Management's Discussion and Analysis of Financial Condition and Results of Operations”

Source:

Anika Therapeutics, Inc.

Posted in: Medical Patent News | Pharmaceutical News

Tags: Facial Wrinkles, Orthopedic, Osteoarthritis, Technology, Therapeutics

Comments (0)

Download PDF Copy

Suggested Reading

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

A review of clinical features, diagnosis, and management of Mpox

A review of clinical features, diagnosis, and management of Mpox

Fungal endophytes: A promising frontier for breast cancer treatment

Fungal endophytes: A promising frontier for breast cancer treatment

New study reveals ketogenic diet's role in combating obesity

New study reveals ketogenic diet's role in combating obesity

Foam technology revolutionizes gene therapy, boosting efficiency and safety

Foam technology revolutionizes gene therapy, boosting efficiency and safety

60 years in the making: Nanoparticles revolutionize nucleotide delivery

60 years in the making: Nanoparticles revolutionize nucleotide delivery

Liraglutide activates key brain circuits to trigger weight loss in obesity

Liraglutide activates key brain circuits to trigger weight loss in obesity

How viral persistence and immune dysfunction drive long COVID

How viral persistence and immune dysfunction drive long COVID

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Scientists uncover two Crohn’s disease subtypes using lab-grown intestines, offering hope for personalized therapies